Background Multidisciplinary cancer conferences (MCCs) are comprised of regular meetings between diverse specialists working together to share clinical decision making in cancer care. The aim of this study is to systematically review and meta-analyze the effect of MCC intervention on overall survival of cancer patients. Methods A systematic literature search was conducted on Ovid MEDLINE, EMBASE and the Cochrane Controlled Register of Trials for studies published up to July 2023. Studies reporting on the impact of MCCs on overall survival of patients were included. A standard random effects model with the inverse-variance weighted approach was used to estimate the pooled hazard ratio of mortality (MCC vs non-MCC) across studies and the heterogeneity was assessed by I2. Publication bias was examined using funnel plot and Egger’s test. Results A total of 134,287 cancer patients from 59 studies were included in our analysis, with 48,467 managed by MCCs and 85,820 in the control arm. Across all cancer types, patients managed by MCCs had an increased overall survival compared to control patients (HR = 0.67, 95%CI = [0.62, 0.71], I2=84%). Median survival time was 30.2 months and 19.0 months in the MCC intervention and control group, respectively. In subgroup analysis, a positive effect of MCC intervention on overall survival was found in breast, colorectal, esophageal, haematological, hepatocellular, lung, pancreatic, and head and neck cancer. Conclusions Overall, our meta-analysis found a significant positive effect of MCCs compared to controls. Further studies are needed to establish nuanced guidelines when optimizing MCC integration for treating diverse cancer patient populations.

中文翻译：

---

多学科癌症会议对总体生存率的影响：荟萃分析

背景 多学科癌症会议 (MCC) 由不同专家之间的定期会议组成，他们共同努力分享癌症护理的临床决策。本研究的目的是系统回顾和荟萃分析 MCC 干预对癌症患者总体生存的影响。方法 对 Ovid MEDLINE、EMBASE 和 Cochrane 对照试验注册库进行系统文献检索，查找截至 2023 年 7 月发表的研究。其中包括报告 MCC 对患者总体生存率影响的研究。采用逆方差加权方法的标准随机效应模型用于估计各研究的死亡率汇总风险比（MCC 与非 MCC），并通过 I2 评估异质性。使用漏斗图和艾格检验检查发表偏倚。结果 我们的分析共纳入了来自 59 项研究的 134,287 名癌症患者，其中 48,467 名接受 MCC 治疗，85,820 名接受对照组治疗。在所有癌症类型中，与对照患者相比，MCC 治疗的患者的总生存期有所延长（HR = 0.67，95%CI = [0.62, 0.71]，I2=84%）。MCC 干预组和对照组的中位生存时间分别为 30.2 个月和 19.0 个月。亚组分析发现，MCC 干预对乳腺癌、结直肠癌、食管癌、血液癌、肝细胞癌、肺癌、胰腺癌和头颈癌的总体生存率产生积极影响。结论 总体而言，我们的荟萃分析发现，与对照组相比，MCC 具有显着的积极作用。在优化 MCC 整合以治疗不同癌症患者群体时，需要进一步研究来建立细致入微的指南。